T Lymphocytes and Anti-CD45 Monoclonal Antibody in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer - Contacts and Locations

T Lymphocytes and Anti-CD45 Monoclonal Antibody in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer

This study is currently recruiting participants.

Study NCT00608257. Last updated on December 2, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00608257

Locations


United States, North Carolina
	Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill	Recruiting
	Chapel Hill, North Carolina, United States, 27599-7295
	Contact: Clinical Trials Office - Lineberger Comprehensive Cancer Cente 877-668-0683; 919-966-4432

United States, Texas
	Dan L. Duncan Cancer Center at Baylor College of Medicine	Recruiting
	Houston, Texas, United States, 77030
	Contact: Clinical Trials Office - Dan L. Duncan Cancer Center at Baylor 713-798-1297
	Methodist Hospital	Recruiting
	Houston, Texas, United States, 77030
	Contact: Vicky Torrano 832-824-7821
	Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital	Recruiting
	Houston, Texas, United States, 77030-2399
	Contact: Vicky Torrano 832-824-7821

Sponsors and Collaborators

Baylor College of Medicine

Investigators


Study Chair:	Stephen Gottschalk, MD	Baylor College of Medicine